Is systematic use of drug-eluting stents justified? Arguments in favour;¿Está justificado el uso sistemático de stents con fármacos? Argumentos a favor

Revista Espanola de Cardiologia

Volumn 57, Issue 2, 2004, Pages 99-108

  Valdés Chávarri, Mariano ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b Portillo de San Antonio 8 5   (Spain)

Author keywords

Drug eluting stents; Efficacy; Paclitaxel; Side effects; Sirolimus

Indexed keywords

METAL; PACLITAXEL; RAPAMYCIN;

ANEURYSM; ARTERY INTIMA; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; RESTENOSIS; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; MULTIMODALITY CANCER THERAPY; NOTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; STENT;

ARTERIAL OCCLUSIVE DISEASES; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CORONARY STENOSIS; DRUG DELIVERY SYSTEMS; HUMANS; PACLITAXEL; SIROLIMUS; STENTS;

EID: 1642601543     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13057259     Document Type: Article

References (72)

1. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al, for the Benestent Study Group. A comparison of balloon-expandable-stent implantion with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
2. Fischman DL, Leon MB, Baim DS, Schatz R, Savage MP, Penn I, et al, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
3. De la Torre JM, Burgos V, González-Enríquez S, Cobo M, Zueco J, Figueroa A, et al. Stent liberador de rapamicina en el tratamiento de lesiones coronarias con alto riesgo de reestenosis. Seguimiento clínico a 6 meses de los primeros 100 pacientes. Rev Esp Cardiol 2004;57:116-22.
4. Ruiz-Nodar JM, Frutos A, Carrillo P, Morillas P, Valero R, Rodríguez JA, et al. Utilización del stent recubierto de rapamicina en la revascularización de lesiones complejas: Estudio con seguimiento clínico y angiográfico. Rev Esp Cardiol 2004;57:123-9.
5. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation 2002; 106:2734-40.
6. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation 2002; 106:2859-66.
7. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: Part I. Circulation 2003; 107:2274-9.
8. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: Part II. Circulation 2003;107:2383-9.
9. Sousa EJ, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IMF, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
10. Degertekin M, Serruys PW, Foley D, Tanabe K, Regar E, Vos J, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantion. Long-term (up to 2 years) clinical. angiographic, and intravascular ultrasound follow-up. Circulation 2002;106:1610-3.
11. Morice MC, Serruys PW, Sousa JE, Fajadet J, Hazashi EB, Perin M, et al, for the RAVEL Study Group. A randomized comparaison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
12. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa E, Colombo A, et al, for the RAVEL Study Group. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting Velocity ballon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
13. Regar E, Serruys PW, Bode C, Holubarsh C, Guermonprey JL, Wijns W, et al, on behalf of the RAVEL Study Group. Angiographic findings of the multicentre randomized study with the sirolimus-eluting bx velocity balloon-expandable stent (RAVEL). Circulation 2002;106:1949-56.
14. Moses JW, Leon MB, Popma JJ, Fitzgerald P, Holmes DR, O'Shaughnessy, et al, for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
15. Schofer J, Schlüter M, Gershlick AH, Wijns W, García E, Schampaert E, et al, for the E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
16. Lemos PA, Lee C-H, Degertekin M, Saia F, Tanabe K, Arampatzis CA, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. J Am Coll Cardiol 2003;41:2093-9.
17. Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction. A clinical and angiographic study. Circulation 2003;108:1927-9.
18. Sousa JE, Costa MA, Abizaid A, Sousa AGMR, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003;107: 24-7.
19. Degertekin M, Regar E, Tanabe K, Smits PC, Van der Giesen WJ, Carlier SG, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience. J Am Coll Cardiol 2003;41:184-9.
20. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerkens U, et al. TAXUS I. Six-and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
21. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al, for the TAXUS II Study Group. Randomized study to asess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
22. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, Van der Giesen WJ, et al. TAXUS III Trial. In-stent restenosis treated with stent-based delivery of pactitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-64.
23. Park SJ, Shim WH, Ho DS, Raizer AE, Park S-W, Hong M-K, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45.
24. Hong MK, Mintz GS, Lee CW, Song J-M, Han K-H, Kang D-H, et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries. A serial volumetric ultrasound analysis from the asian paclitaxel-eluting stent clinical trial (ASPECT). Circulation 2003;107:517-20.
25. Mintz GS, Tinana A, Hong MK, Lee CW, Kim J-J, Feranot NE, et al. Impact of preinterventional arterial remodeling on neointitrial hyperplasia after implantation of (non-polymer-encapsulated) paclitaxel-coated stents. A serial volumetric ultrasound analysis from the asian paclitaxel-eluting stent clinical trial (ASPECT). Circulation 2003;108:1295-8.
26. Schampaert E. The canadian multicenter, randomized, double-blind trial of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery disease [abstract]. Circulation 2003;108:3193.
27. Costa RA, Lansky A, Mehran R, Tsuchiya Y, Cristea E, Negoita M, et al. Everolimus-eluting stent for the treatment of de novo coronary lesions-angiographic follow-up of the FUTURE trial [abstract]. Circulation 2003;108:3191.
28. Grube E, Buellesfeld L, Mueller R, Staberock M, Selbach G, Schmidt T, et al. First human experience using a new everolimus stent coating: Procedural and six-month follow-up results of the FUTURE trial. J Am Coll Cardiol 2003;41(Suppl A): 1006-183.
29. Stone G, Ellis S, Cox D, Hermiller J, O'Shaughnessey C, Mann JT, et al. The pivotal US study of the slow-rate release polymer-based paclitaxel-eluting TAXUS stent in patients with de novo coronary lesions [abstract]. Circulation 2003;108:IV533.
30. Ellis S, Stone G, Popma J, Weissman N, Hermiller J, Cox DA, et al. The TAXUS IV study: Final angiographic results [abstract]. Circulation 2003;108:IV532.
31. Kereiakes D, Moses JW, Leon MB, O'Shaughnessey C, Caputo R, Brown C, et al. Durable clinical benefits following CYPHER coronary stent deployment: SIRIUS study 2-year results [abstract]. Circulation 2003;108:IV532.
32. Ako J, Morino Y, Honda Y, Sonoda S, Terashima M, Hassan A, et al. Effects of sirolimus-eluting stents in diabetics patients: Volumetric intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2003;41(Suppl A):1198-80.
33. Moses JW, Kereiakes D, Williams DO, Douglas J, Lambert C, Simonton C, et al. Should sirolimus-eluting stents be the new standard for left anterior descending artery? A SIRIUS substudy. J Am Coll Cardiol 2003;41(Suppl A):1198-279.
34. Guagliumi G, Hoffman R, Schofer J, Musumeci G, Petronio AS, Reimers B, et al. Intravascular ultrasound findings in the multicenter, randomized, double blind e-SIRIUS trial [abstract]. Circulation 2003;108:3185.
35. Schofer J, Breithardt G, Gerslick A, Wijns W, García E, Kuntz R, et al. Nine-month subgroup analysis of the E-SIRIUS trial: direct stenting vs predilatation [abstract]. Circulation 2003;108: 2431.
36. Morice MC, Serruys P, Costantini C, Wuelfert E, Wijns W, Fajadet J, et al, on behalf of the RAVEL trial investigators. Two-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting bx velocity(tm) stent in the treatment of patients with de-novo native coronary artery lesions. J Am Coll Cardiol 2003;41(Suppl A):805-1.
37. Guagliumi G, Sousa E, Urban P, Gershlick A, Schofer J, Lotan C, et al. Sirolimus-eluting stent in routine clinical practice: A 6-month follow-up report from the international E-CHYPHER registry [abstract]. Circulation 2003;108:2437.
38. Abizaid A, Chan CH, Kaul U, Patel T, Tan HC, Sutandar Dr, et al. Real world evaluation of slow-release, polymer-based, paclitaxel-eluting TAXUS stents in native coronary arteries: The Wisdom International [abstract]. Circulation 2003;108:2436.
39. Lemos PA, Saia F, Arampatzis CA, Hoye A, Tanabe K, Degertekin M, et al. Unrestricted utilization of sirolimus-eluting stent implantation in the real world reduces events compared with previous strategies using conventional bare stents. A study of 1200 consecutive patients from the RESEARCH registry [abstract]. Circulation 2003;108:2430.
40. Igual M, Vettiger B, Amann P, Rickli H, Syed R, Vuilliomenet A, et al. The Swiss registry for sirolimus eluting stents in complex coronary lesions [abstract]. Eur Heart J 2003;24(Suppl): 3658.
41. Hamm CW, Schneider S, Senges J, for the German CYPHER stent registry. Initial results of the german drug-eluting stent registry [abstract]. Circulation 2003;108:2434.
42. Suárez de Lezo J, Medina J, Pan M, Romero M, Segura J, Delgado A, et al. Sirolimus-eluting stents for the treatment of unprotected left-main coronary lesions [abstract]. Circulation 2003;108:1885.
43. Chieffo A, Michev I, Stankoviv G, Airoldi F, Montorfano M, Orlic D, et al. Sirolimus-eluting stents in unprotected left main [abstract]. Eur Heart J 2003;24(Suppl):2255.
44. Airoldi F, Spanos V, Stankovic G, Di Mario C, Chieffo A, Briguori C, et al. Bifurcational coronary artery lesion treatment with rapamicine-eluting stents: Results from a single center experience. J Am Coll Cardiol 2003;41(Suppl A):839-43.
45. Tanabe K, Lemos PA, Lee C-H, Degertekin M, Regar E, Arampatzis AC, et al. The impact of sirolimus-eluting stents on the outcome of patients with bifurcation lesions. J Am Coll Cardiol 2003;41(Suppl A):1030-180.
46. Costa MA, Moses JW, Leon MB, Teirstein PS, Yakubov S, Carter AJ, et al. Sirolimus-eluting stent for the treatment of bypass graft disease: The initial US experience. J Am Coll Cardiol 2003;41(Suppl A):1030-183.
47. Costa M, Gilmore P, Carter A, Teirstein P, Yakubov S, Sasseen B, et al. Sirolimus-eluting stents for the treatment of bypass graft disease: Long-term results of the initial US experience [abstract]. Circulation 2003;108:1806.
48. Medina A, Suárez de Lezo J, Pan M, Hernández E, Romero M, Delgado A, et al. Inmediate and late results of drug-eluting stents for the treatment of in-stent restenosis [abstract]. Circulation 2003;108:1884.
49. Emig U, Wermer GS, Scwarz G, Figulla HR. Sirolimus-eluting stents for the treatment of recurrent instent-restenosis: A worst case scenario to prove the effectiveness of drug-eluting stents [abstract]. Circulation 2003;108:2692.
50. Terstein P, Moses JW, Leon MB, Kao J, Bass T, Costa MA, et al. Use of the sirolimus-eluting bx VELOCITYtm stent for failed brachytherapy in recurrent in-stent restenosis: Results from the SECURE registry [abstract]. Circulation 2003;108:1889.
51. Commeau P, Barragan PT, Roquebert PO, Bouvier JL, Comet B, Macaluso G. Treatment of in-stent restenosis using sirolimus-eluting stents: ISR II registry. J Am Coll Cardiol 2003;41(Suppl A):839-45.
52. Nakamura S, Muthusumay T, Bae J-H, Cahyadi YH, Pachirat O. Impact of sirolimus-eluting stents on the outcome of patients with chronic total occlusions: Multicenter registry in Asia [abstract]. Circulation 2003;108:1888.
53. Tavano D, Airoldi F, Montorfano M, Carlino M, Chieffo A, Michev Y, et al. Immediate-term and midterm clinical results of sirolimus-eluting stents in coronary chronic total occlusions. Am J Cardiol 2003;92(Suppl):449.
54. Orlic D, DiMario C, Bonizzoni E, Satnkovic G, Corvaja N, Sangiorgi G, et al. Multivessel coronary artery stenting with sirolimus-eluting stent implantation: Inmediate and midterm results. Am J Cardiol 2003;92(Suppl):211.
55. Lemos PA, Arampatzis AC, Hoye A, Tanabe K, Van der Giessen WJ, De Feyter P, et al. Sirolimus-eluting stent implantation in very small coronary-vessels treated in RESEARCH Registry [abstract]. Eur Heart J 2003;24(Suppl):521.
56. Meier B. SVELTE trial: A multicenter, historically controlled study in patients with de novo native coronary artery lesions in small vessels treated with the CYPHER stent. Am J Cardiol 2003;92(Suppl):207.
57. Degertekin M, Saia F, Lemos PA, Lee CH, De Feyter P, Sianos G, et al. Efficay of sirolimus-eluting stent implantation in long (> 36 mm) stented segments. A RESEARCH substudy [abstract]. Eur Heart J 2003;24(Suppl):3654.
58. Saia F, Lemos PA, Lee C-H, Arampatzis CA, Hoye A, Tanabe K, et al. Comparison between sirolimus-eluting stents and conventional interventional strategies for patients with acute myocardial infarction. Results of the RESEARCH registry [abstract]. Circulation 2003;108:1890.
59. Weber F, Schneider H, Laubenthal F, Nienaber CA, Sabin GV, on behalf of German CHYPHER (TM) registry. Sirolimus-eluting stent Cypher in patients with acute myocardial infarction [abstract]. Eur Heart J 2003;24 (Suppl):528.
60. Safian RD, Zidar J, Hermiller J, Greenbaum J, Goldberg S. Coronary stents. En: The Manual of Interventional Cardiology: 3th ed. Michigan: Physicians' Press, 2001; p. 511-615.
61. Regar E, Serruys PW. El estudio RAVEL. Reestenosis del cero por ciento: ¡un sueño del cardiólogo hecho realidad! Rev Esp Cardiol 2002;55:459-62.
62. Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003;107:2178-80.
63. Kapoor S. The angiographic pattern of restenosis after paclitaxel-eluting stents. Am J Cardiol 2003;92(Suppl):124.
64. Regar E, Lemos PA, Lee C-H, Tanabe K, Saia F, Degertekin M, et al. Subacute stent trombosis after sirolimus-eluting stent implantation in daily practice: Results from the rapamycin eluting-stent evaluated at Rotterdam hospital (research) registry. J Am Coll Cardiol 2003;41(Suppl A):1053-202.
65. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions. An intravascular ultrasound analysis. Circulation 2003;108:2747-50.
66. Leon MB, Moses JW, Weisz G, Teirstein PS, Fitzgerald P, Holmes DR, et al. The frequency and consequences of angiographic aneurysms after sirolimus-eluting stents: Results from SIRIUS. J Am Coll Cardiol 2003;41(Suppl A):1030-181.
67. Degertekin M, Lemos PA, Lee CH, Tanabe K, Sousa JE, Abizaid A, et al. Intravascular ultrasound evaluation after sirolimus eluting stent implantion for de novo and in-stent restenosis lesions. Eur Heart J 2004;25:32-8.
68. Sousa JE, Costa MA, Abizaid A, Rensing BJ, Abizaid AS, Tanjura LF, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
69. Sousa JE, Costa MA, Sousa AGMR, Abizaid AC, Seixas AC, Abizaid AS, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-3.
70. O'Neill WW, Leon MB. Drug-eluting stents. Costs versus clinical benefit. Circulation 2003;107:3008-11.
71. Cohen DJ, Bakhai A, Shi C, Githiora L, Berezin RH, Caputo RP, et al. Cost-effectiveness of sirolimus drug-eluting stents for the treatment of complex coronary stenoses: Results from the randomized SIRIUS trial. J Am Coll Cardiol 2003;41(Suppl A):805-2.
72. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents. Cost versus clinical benefit. Circulation 2003;107:3003-7.